dextran sulfate low molecular weight

Dextran sulfate low molecular weight (LMW-DS) is a sulfated polysaccharide derivative currently being investigated as a potential disease-modifying therapy for amyotrophic lateral sclerosis (ALS). Developed in part by researchers at Oslo University Hospital, LMW-DS is hypothesized to interfere with the pathological aggregation of TAR DNA-binding protein 43 (TDP-43), a hallmark proteinopathy found in the motor neurons of nearly all ALS patients. By binding to misfolded proteins, LMW-DS may prevent the formation of toxic aggregates and facilitate their clearance. Additionally, the drug is thought to modulate neuroinflammatory pathways and stabilize the blood-brain barrier, which are often compromised in neurodegenerative conditions. Clinical trials, such as the Phase 2 study conducted by Oslo University Hospital, evaluate the safety and efficacy of LMW-DS administered via intravenous infusion to slow the progression of motor neuron loss and functional decline in ALS patients.

Other names

low molecular weight dextran sulfatedextran sulfate sodium low molecular weightLMWDS